Descrizione

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 milioni da 2022 A 2028, ottenendo un CAGR di 16.1% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, applicazione, biomarker type, tecnologia, e regione. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), altri (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 e si prevede che manterrà la sua quota durante il periodo di previsione. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, altri. In 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), altri. Tra questi, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. In termini di geografia, the global liquid biopsy market has been segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., Becton Dickinson and Company, Berry Genomics Co. Ltd., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Therapy: oncology, noninvasive prenatal testing (NIPT), altri (e.g. organ transplant)
Applicazione: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, altri
Tecnologia: next-generation sequencing (NGS), polymerase chain reaction (PCR), altri
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global liquid biopsy market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Liquid biopsy market overview
Parte 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– Altri (e.g. organ transplant)
Parte 4. Market breakdown by application
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Parte 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– Altri
Parte 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– Altri
Parte 7. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 8. Aziende chiave
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Ltd.
– Becton, Dickinson and Company
– Berry Genomics Co., Ltd.
– BGI Group
– Biocartis Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Rad Laboratories, Inc.
– Bio-Techne Corp.
– CareDx, Inc.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, Inc.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
Informazioni su StrategyHelix
Disclaimer